News | September 17, 2024
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revolutionary technology will further boost OneSource’s scientific services offerings
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Subscribe To Our Newsletter & Stay Updated
